Stock Market Reviews

VTYX (Ventyx Biosciences, Inc.) News

Get the latest news, insights, and market updates on VTYX (Ventyx Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
  Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
  Feb 14, 2026 - $VTYX
• Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
  This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
  Feb 14, 2026 - $VTYX
• Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
  The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.
  Jan 29, 2026 - $VTYX
• Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple
  What Recent Returns Tell You About Ventyx Biosciences Ventyx Biosciences (VTYX) has drawn fresh attention after a strong share price move, with the stock showing a 52% gain over the past month and a very large 1 year total return. For context, the company remains a clinical stage biopharmaceutical business with no reported revenue and a net loss of US$106.607 million. Recent price action is being driven by expectations around its drug pipeline rather than current sales or earnings. Short term...
  Jan 25, 2026 - $VTYX
• Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
  Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.
  Jan 20, 2026 - $VTYX
• Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?
  The pharmaceutical leader has plenty of cash and is using it effectively.
  Jan 17, 2026 - $VTYX
• Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
  After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.
  Jan 13, 2026 - $VTYX
• BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
  BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.
  Jan 12, 2026 - $VTYX
• Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences
  Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive agreement to acquire Ventyx Biosciences, Inc., which is a clinical-stage biopharmaceutical company that develops innovative oral therapies for patients with inflammatory-mediated diseases. Ventyx Biosciences, Inc. […]
  Jan 10, 2026 - $VTYX
• Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
  NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.
  Jan 9, 2026 - $VTYX